Core Viewpoint - The completion of the H-share full circulation by Fuhong Hanlin marks a significant step in the company's equity structure and capital operations, enhancing liquidity and governance standards while supporting its global strategy and innovation efforts [1] Group 1: H-share Full Circulation - A total of 183 million non-listed shares have been converted into H-shares, which will start trading on the Hong Kong Stock Exchange on February 5, 2026 [1] - After the full circulation, the total number of H-shares will increase to 346 million [1] - The full circulation is expected to attract more international investors, benefiting the long-term development of the company and its shareholders [1] Group 2: Product Portfolio and Market Presence - Fuhong Hanlin has 10 products approved for sale in over 60 markets globally [1] - The company has achieved significant milestones in major biopharmaceutical markets, with 4 products receiving FDA approval and 4 products obtaining EMA authorization [1] - The company has a diversified pipeline with over 50 early-stage molecules, demonstrating its commitment to high-quality research and development aligned with international standards [1]